{
    "nctId": "NCT00629278",
    "briefTitle": "Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer",
    "officialTitle": "SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2500,
    "primaryOutcomeMeasure": "Disease-free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of infiltrating primary breast cancer\n\n  * Stage I-IIIA disease\n  * Resected tumor with free margins (i.e., no neoplastic cells on the resected margin)\n\n    * Must have node-negative sentinel node or complete axillary clearance\n\n      * Axillary clearance required for micrometastasis (between 0.2 and 2 mm) in the sentinel node but not for isolated tumor cells\n    * Treatment is scheduled to begin within 10 weeks from the date of surgery\n\n      * Date of the last surgery will be taken into account for patients undergoing re-excision of positive margins or axillary lymph node dissection after positive sentinel node biopsy\n* Node positivity or node negativity AND \u2265 1 of the following:\n\n  * T \\> 2 cm\n  * Grade 3\n  * Presence of lymphovascular invasion\n  * Ki 67 \\> 20%\n  * Age 35 years\n  * Hormone receptor negativity (\\<10%)\n* HER2-positive tumor (3+ by IHC or FISH+ according to the American Society of Clinical Oncology guidelines \\[i.e., \\> 2.2; in case of polysomy, with \u2265 6 gene copies\\])\n* Estrogen receptor-positive and/or progesterone receptor-positive disease\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Pre- or postmenopausal status\n\n  * Postmenopausal status defined by \u2265 1 of the following:\n\n    * At least 60 years of age\n    * Less than 60 years of age and amenorrheic for \u2265 12 months prior to day 1\n    * Less than 60 years of age and amenorrheic for \\< 12 months prior to day 1 with luteinizing hormone and follicle-stimulating hormone values within postmenopausal range OR without a uterus\n    * Prior bilateral oophorectomy\n    * Prior radiation castration with amenorrhea for \u2265 6 months\n* ECOG performance status 0-1\n* Suitable for adjuvant chemotherapy\n* WBC \\> 3,000/mcL\n* ANC \\> 1,500/mcL\n* Platelet count \\>100,000/mcL\n* Total bilirubin normal\n* AST and ALT 2.5 times upper limit of normal\n* Creatinine normal\n* Cardiac ejection fraction normal as measured by ECHO or MUGA scan\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for \u2265 3 months after completion of study therapy\n* No contraindication to anthracycline, cyclophosphamide, fluorouracil, paclitaxel, or trastuzumab (Herceptin\u00ae) treatment\n* No uncontrolled intercurrent illness including, but not limited to, the following:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness/social situations that would limit compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* See Patient Characteristics\n* No prior chemotherapy, endocrine therapy, or radiotherapy\n* No other concurrent investigational agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}